Importantly, high PRAME levels were found to correlate with advanced stages of disease in melanoma [4], neuroblastoma [5], serous ovarian adenocarcinoma [6], and chronic myeloid leukaemia [7], and to constitute an independent prognostic factor of poor clinical outcome in breast cancer [8], [9]. The gene discussed is PRAME; the disease is breast cancer.